Trial Profile
A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Raltegravir (Isentress) and Buprenorphine
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Buprenorphine/naloxone (Primary) ; Raltegravir (Primary)
- Indications Opioid-related disorders
- Focus Pharmacokinetics
- 20 Nov 2012 Primary endpoint amended as reported by ClinicalTrials.gov record.
- 20 Mar 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 20 Mar 2010 Actual patient number (12) added as reported by ClinicalTrials.gov.